Xiamen Wiz Biotech officially listed for trading
Xiamen Wiz Biotech Co., Ltd. was listed and traded on the New Third Board on February 5, 2017. The stock name is Wiz Biotech (stock code 839355).
Xiamen Wiz Biotech Co., Ltd is a biological high-tech enterprise committed to the field of rapid diagnostic reagents, research and development, production and sales. Wiz Biotech won the honor of the national high-tech enterprise, the Fujian Province "100 people plan", Xiamen City "double 100 plan" settled enterprise, and is "Xiamen 13th Five-Year "biological medicine and health industry development plan" key support enterprises. Wiz Biotech is located in the biomedical industrial Park, Haicang District, Xiamen City, with a first-class R & D center and an international standard GMP factory building. It has passed the national in vitro diagnostic reagent quality management standard and the European Union industry quality management system standard ISO13485 certification. It has a medical device manufacturing enterprise license and industrial production qualification.
The company has senior R & D personnel and marketing management personnel with working experience in famous domestic and foreign biomedical enterprises. The R & D team includes well-known scientists at home and abroad. With advanced technology and projects, Wiz has accumulated stable production technology and solid R & D strength. At present, the company has a number of core technology patents. As of December 2016, the company has applied for 10 patents and obtained 9 authorized patents, including 4 invention patents, 5 utility models, and one invention under actual examination. At the same time, the company carries out research and development cooperation with the Chinese Academy of Sciences, jointly builds the "Joint Laboratory of Medical Diagnosis Application Technology", and establishes the production and research cooperation platform, to further ensure that the company can quickly and effectively complete the R&D and industrialization of related products.
The current projects of the company are POCT in vitro diagnostic reagents and related instruments, and it has mature immunochromatography technology platforms, including colloidal gold, latex and fluorescence quantitative immunochromatography platform. At present, the company can produce 5 series of about 50 kinds of products, including hormones, infectious diseases, tumor markers, drugs and myocardial markers, etc. At the same time, the company has also carried out the development of molecular diagnostics technology and products, and introduced an innovation team led by experts of the National Thousand Talents Plan to develop the technical platform and products of molecular diagnostics combined with microfluidic, which has achieved initial results.
With the purpose of "focus on diagnostic techniques to improve the quality of life", the company is committed to creating an innovation platform for in vitro diagnostic reagent technology, developing new rapid diagnostic reagents and instruments to meet the market demand, constantly innovating and forging ahead, constantly improving the detection level of diseases, and escorting the life and health cause of the public.
With the successful listing on the New Third Board as an opportunity, Wiz Biotech will carry out sincere employment, treat people with talents, with a more open culture and a more inclusive mentality, to better serve customers, provide better returns to investors, and realize a new take-off!
